While bio-based polymers have been a hot topic for some years now, it’s grown increasingly clear that where plastics end up is at least as important as how they’re made. Current recycling technologies are limited, bringing either low-quality recyclates or high processing costs. But enzymes now offer a glimmer of hope. Working with the common plastic PET, a French firm is trying to prove biotech approaches can close the loop in the material’s life cycle. They hope they’ll soon be able to recycle the plastic endlessly and affordably.
Ablynx’ SLE antibody vobarilizumab miss endpoint
Latest NewsBelgian nanobody maker Ablynx’ IL-6 receptor blocker vobarilizumab didn’t met the primary endpoint of dose response at 24 weeks in a Phase II study enroling 312 patients with severe, active seropositive systemic lupus erythematosus (SLE).
MorphoSys files registration for ADS offering
Latest NewsAntibody specialist MorphoSys AG has filed a Registration Statement on Form F-1 with the U.S. Securities and Exchange Commission (SEC) for a proposed Nasdaq offering of American Depositary Shares (ADS)
We need creative investment to tackle AMR
OpinionBiotech for breaking down a sea of waste
BackgroundWhile bio-based polymers have been a hot topic for some years now, it’s grown increasingly clear that where plastics end up is at least as important as how they’re made. Current recycling technologies are limited, bringing either low-quality recyclates or high processing costs. But enzymes now offer a glimmer of hope. Working with the common plastic PET, a French firm is trying to prove biotech approaches can close the loop in the material’s life cycle. They hope they’ll soon be able to recycle the plastic endlessly and affordably.
Deinove to licence antibiotic leads form RedX Pharma
Latest NewsFrench antibiotics player Deinove has inked a licence option agreement with Redx Pharma plc concerning a new class of synthetic preclinical topoisomerase blockers to treat infections caused by Gram-negative ESKAPE pathogens.
Bioeconomy: Germany to lose pole position
Latest NewsThe German Bioeconomy Council said policymakers would risk Germany’s leadership in bioeconomy if they don’t capitalise on new technology options resulting from the ongoing merger of digital and bio-technologies.
Søren Tulstrup appointed CEO of Hansa Medical
AppointmentsHansa Medical AB, a biopharmaceutical company developing novel immunomodulatory enzymes, today announced that the board of directors have appointed Søren Tulstrup as new President and CEO of Hansa Medical effective today March 20, 2018.
Eylea met Phase III endpoint in diabetic retinopathy
Latest NewsVEGF blocker Eylea (aflibercept), which is co-developed for eye diseases by Bayer HealthCare and Regeneron under a deal signed in 2006, has met the 24-week primary endpoint of the pivotal Panorama Phase III trial.
Lundbeck acquiring Prexton in €905m deal
Latest NewsH. Lundbeck A/S has announced it will acquire Dutch Prexton Therapeutics B.V., a one-programme company developing the allosteric metabotropic glutamate receptor subtype 4 (mGluR4) modulator foliglurax (PXT002331) in Parkinson’s Disease.
Equipment, plates and seals from Porvair Sciences for automation in drug discovery
ProductsDunn Labortechnik presents a special product range from Porvair Sciences for sample preparation and improved productivity in drug discovery: evaporator, manifold, plate sealer and plates.